a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers
This clinical trial is evaluating a new treatment for diabetic foot ulcers that have not healed with standard wound care. The treatment, called BIOxHEAL, is a single-layer biologic made from donated human amniotic membrane, which is placed directly on the wound to help it close. The study is currently recruiting participants in Boardman, United States, and is expected to start in October 2026. The main goal is to determine whether adding BIOxHEAL to standard wound care helps more ulcers heal completely by 12 weeks compared to standard care alone. The trial includes a randomized controlled portion and a non-randomized sentinel cohort. This research is important because diabetic foot ulcers are a serious complication of diabetes that can lead to amputation if not treated effectively. In China, where diabetes is increasingly common, there is growing interest in advanced wound care technologies, and this trial represents one of the innovative biologic approaches being explored globally.
Key takeaways
- The trial tests BIOxHEAL, a biologic treatment made from human amniotic membrane, which may help speed up healing in hard-to-treat diabetic foot ulcers.
- Participants will be randomly assigned to receive either BIOxHEAL plus standard care or standard care alone, with weekly clinic visits for up to 12 weeks.
- The study is currently recruiting at a single location in Boardman, United States, so it may not be accessible to patients in China.
- For patients with non-healing ulcers, this trial offers hope for a new option that could reduce the risk of amputation.
- Ask your doctor about clinical trials and whether newer biologic treatments are available at specialist wound care centers in China.
Read the full paper / source →
This content summarizes published medical research for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making treatment decisions.
Free consultation
Could this treatment help you?
Our DFU specialists review every inquiry personally. Tell us about your situation — response within 48 hours, no commitment required.
This website provides medical-information science popularization only. It does NOT provide online diagnosis, prescriptions, or medical advice. Consult a licensed physician for any medical decision.
Editor's note
BIOxHEAL is designed to give your body a helping hand by providing a biological scaffold that supports new tissue growth and closes the wound. If your ulcer has not healed with standard care and you're facing the possibility of amputation, this type of treatment aims to offer a less invasive option that could save your foot. While this specific trial is in the United States, similar placental-derived products are becoming available at some of China's leading DFU centers, so it's worth asking your doctor about them. If you're considering overseas treatment, keep in mind that travel and cost can be significant, but trials like this one pave the way for future therapies that may soon be more widely accessible.